Business Context and Reporting Period
Company: Inmune Bio, Inc. (INMB)
Filing Type: Form 8-K (Current Report)
Reporting Date: June 27, 2025 (Event Date); June 30, 2025 (Closing Date)
Context: The Company announced and subsequently closed a registered direct offering of common stock to raise capital.
Key Financial Metrics
This filing reports on a specific capital raise event rather than periodic financial performance. Key metrics related to the transaction include:
- Shares Issued: 3,000,000 shares of common stock.
- Offering Price: $6.30 per share.
- Gross Proceeds: Approximately $18.9 million.
- Placement Agent Fee: 7.0% of gross proceeds (paid to A.G.P./Alliance Global Partners).
- Net Proceeds: Not explicitly stated; calculated as gross proceeds minus fees and expenses.
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions as this is a transactional report, not a financial statement.
Material Changes
The primary material change is the increase in the Company's share count and cash position resulting from the Offering:
- Capital Structure: Issuance of 3,000,000 new shares to two healthcare-focused institutional investors.
- Liquidity: Influx of approximately $18.9 million in gross cash proceeds.
- Ownership: Dilution of existing shareholders due to the new issuance.
Guidance, Outlook, and Risks
Management Commentary: The Company utilized a shelf registration statement (File No. 333-279036) declared effective on August 7, 2024, to execute this at-the-market offering under Nasdaq rules.
Risks and Contingencies:
- Transaction Costs: The Company is obligated to reimburse certain legal and other expenses in addition to the 7.0% placement fee.
- Market Conditions: The offering was priced at-the-market, reflecting current market conditions as of June 27, 2025.
The filing text does not provide specific forward-looking guidance, updated clinical trial timelines, or revised financial outlooks beyond the completion of this capital raise.
Investor Verification Checklist
- Verify the final net proceeds after deducting the 7.0% placement fee and reimbursed expenses.
- Confirm the updated total share count and fully diluted ownership structure post-offering.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for any specific covenants or restrictions on the use of proceeds.
- Check subsequent filings for the Company's intended allocation of the $18.9 million raised.